A Multiparametric MRI-based Radiomics Model for Stratifying Postoperative Recurrence in Luminal B Breast Cancer
This study aims to develop an MRI-based radiomics model to assess the likelihood of recurrence in luminal B breast cancer. The study analyzed medical images and clinical data from 244 patients with luminal B breast cancer. Of 244 patients, 35 had experienced recurrence and 209 had not. The patients were randomly divided into the training set (51.5 ± 12.5 years old;n = 171) and the test set (51.7 ± 11.3 years old;n = 73) in a ratio of 7:3. The study employed univariate and multivariate Cox regression along with the least absolute shrinkage and selection operator (LASSO) regression methods to select rad...
Source: Journal of Digital Imaging - February 29, 2024 Category: Radiology Source Type: research
Palbociclib in advanced stage hormone receptor-positive breast cancer: real-world data from a Chilean multicentre registry
CONCLUSION: Our real-world data show that first-line CDKi + ET provides a statistically significant benefit in OS versus ≥second line in HR+/HER2- ABC patients.PMID:38414945 | PMC:PMC10898906 | DOI:10.3332/ecancer.2023.1636 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - February 28, 2024 Category: Cancer & Oncology Authors: Benjam ín Walbaum Jos é Miguel Reyes Pablo Rodriguez Sabrina Mu ñiz Lidia Medina Carolina Iba ñez Tomas Merino Mauricio P Pinto Maria Loreto Bravo Francisco Acevedo Jos é Bennett Cesar Sanchez Source Type: research
Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis
The role of simultaneous neoadjuvant endocrine therapy in chemotherapy in HR+HER2- breast cancer continues to be controversial. This systematic review and meta-analysis was conducted to further evaluate the effectiveness and safety of this strategy for HR+HER2- breast cancer patients. Trials in which HR+HER2- breast cancer patients were randomly assigned to either single or simultaneous endocrine-assisted neoadjuvant chemotherapy were eligible for inclusion. The prime endpoint was the pathological complete response (pCR) rate. The clinical response (complete clinical response: CR, partial response: PR) and safety were seco...
Source: Frontiers in Endocrinology - February 28, 2024 Category: Endocrinology Source Type: research
Thyroid Metastases from Breast Cancer Case Report and Literature Review
CONCLUSION: Given the unusual clinical indicators, identifying heterochronic thyroid metastases in patients with tumors poses a distinct challenge, requiring clinicians to navigate the follow-up process with heightened sensitivity. The key lies in timely detection and early intervention, factors that can significantly enhance the overall quality of life for patients.PMID:38409692 | DOI:10.2174/0115680096274465240129055950 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Yumei Guan Qinjun Ma Yiqing Zhang Jiuda Zhao Xinjian Guo Source Type: research
Thyroid Metastases from Breast Cancer Case Report and Literature Review
CONCLUSION: Given the unusual clinical indicators, identifying heterochronic thyroid metastases in patients with tumors poses a distinct challenge, requiring clinicians to navigate the follow-up process with heightened sensitivity. The key lies in timely detection and early intervention, factors that can significantly enhance the overall quality of life for patients.PMID:38409692 | DOI:10.2174/0115680096274465240129055950 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Yumei Guan Qinjun Ma Yiqing Zhang Jiuda Zhao Xinjian Guo Source Type: research
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
Eur J Pharmacol. 2024 Feb 23:176424. doi: 10.1016/j.ejphar.2024.176424. Online ahead of print.ABSTRACTThe therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). Fulvestrant is the first approved SERD with proven efficacy and good tolerability in clinical practice. However, secondary drug resistance, low receptor affinity, and parental administration stimulated the search for new oral SERDs opening a new therapeutic era in ER + breast cancer. Elaces...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Giorgio Guglielmi Marzia Del Re Leila Sadeghi Gol Carmelo Bengala Romano Danesi Stefano Fogli Source Type: research
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
Eur J Pharmacol. 2024 Feb 23:176424. doi: 10.1016/j.ejphar.2024.176424. Online ahead of print.ABSTRACTThe therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). Fulvestrant is the first approved SERD with proven efficacy and good tolerability in clinical practice. However, secondary drug resistance, low receptor affinity, and parental administration stimulated the search for new oral SERDs opening a new therapeutic era in ER + breast cancer. Elaces...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Giorgio Guglielmi Marzia Del Re Leila Sadeghi Gol Carmelo Bengala Romano Danesi Stefano Fogli Source Type: research
Concurrent factors associated with adherence to adjuvant endocrine therapy among women with non-metastatic breast cancer
ConclusionsMedication-taking self-efficacy and employment status were associated with AET adherence above other related factors.Implications for Cancer SurvivorsEnhancing patients ’ confidence in their ability to take AET for breast cancer may represent an important intervention target to boost adherence. (Source: Journal of Cancer Survivorship)
Source: Journal of Cancer Survivorship - February 24, 2024 Category: Cancer & Oncology Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Breast Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Genitourinary Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast
CONCLUSIONS: Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.PMID:38393465 | DOI:10.1007/s11033-023-09119-4 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - February 23, 2024 Category: Molecular Biology Authors: Sneha Pandithar Daniel Galke Ahone Akume Artem Belyakov Dominick Lomonaco Amirah A Guerra Jay Park Olivia Reff Kideok Jin Source Type: research
The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast
CONCLUSIONS: Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.PMID:38393465 | DOI:10.1007/s11033-023-09119-4 (Source: Mol Biol Cell)
Source: Mol Biol Cell - February 23, 2024 Category: Molecular Biology Authors: Sneha Pandithar Daniel Galke Ahone Akume Artem Belyakov Dominick Lomonaco Amirah A Guerra Jay Park Olivia Reff Kideok Jin Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Breast Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Genitourinary Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
